SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-268807
Filing Date
2023-11-02
Accepted
2023-11-02 07:05:51
Documents
14
Period of Report
2023-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d559654d8k.htm   iXBRL 8-K 26061
2 EX-99.1 d559654dex991.htm EX-99.1 90671
6 GRAPHIC g559654g1102054612750.jpg GRAPHIC 5859
  Complete submission text file 0001193125-23-268807.txt   256227

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20231102.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20231102_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20231102_pre.xml EX-101.PRE 10824
8 EXTRACTED XBRL INSTANCE DOCUMENT d559654d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 231370027
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences